Orgenesis Inc. (ORGS)

USD 2.4

(10.6%)

Total Liabilities Summary of Orgenesis Inc.

  • Orgenesis Inc.'s latest annual total liabilities in 2023 was 35.53 Million USD , up 12.26% from previous year.
  • Orgenesis Inc.'s latest quarterly total liabilities in 2024 Q2 was 46.36 Million USD , down -20.69% from previous quarter.
  • Orgenesis Inc. reported annual total liabilities of 31.65 Million USD in 2022, up 49.24% from previous year.
  • Orgenesis Inc. reported annual total liabilities of 21.21 Million USD in 2021, down -15.01% from previous year.
  • Orgenesis Inc. reported quarterly total liabilities of 58.46 Million USD for 2024 Q1, up 64.54% from previous quarter.
  • Orgenesis Inc. reported quarterly total liabilities of 33.95 Million USD for 2023 Q1, up 7.28% from previous quarter.

Annual Total Liabilities Chart of Orgenesis Inc. (2023 - 2008)

Historical Annual Total Liabilities of Orgenesis Inc. (2023 - 2008)

Year Total Liabilities Total Liabilities Growth
2023 35.53 Million USD 12.26%
2022 31.65 Million USD 49.24%
2021 21.21 Million USD -15.01%
2020 24.95 Million USD -71.12%
2019 86.41 Million USD 84.66%
2018 46.79 Million USD 81.75%
2017 25.74 Million USD 12.4%
2016 22.9 Million USD -49.3%
2015 45.18 Million USD 764.3%
2014 5.22 Million USD 143.33%
2013 2.14 Million USD 553.63%
2012 328.72 Thousand USD 286.67%
2011 85.01 Thousand USD 612.12%
2010 11.93 Thousand USD 98.97%
2009 6000.00 USD 71.43%
2008 3500.00 USD 0.0%

Peer Total Liabilities Comparison of Orgenesis Inc.

Name Total Liabilities Total Liabilities Difference
America Great Health 4.82 Million USD -636.482%
Ampio Pharmaceuticals, Inc. 2.37 Million USD -1395.581%
Aridis Pharmaceuticals, Inc. 38.92 Million USD 8.714%
Biora Therapeutics, Inc. 132.63 Million USD 73.209%
Bio-Path Holdings, Inc. 2.77 Million USD -1178.697%
Better Therapeutics, Inc. 23.84 Million USD -49.044%
Calithera Biosciences, Inc. 8.28 Million USD -328.959%
Comera Life Sciences Holdings, Inc. 9.97 Million USD -256.269%
Gene Biotherapeutics, Inc. - USD -Infinity%
eFFECTOR Therapeutics, Inc. 26.33 Million USD -34.914%
Eloxx Pharmaceuticals, Inc. 31.78 Million USD -11.805%
Evelo Biosciences, Inc. 69.43 Million USD 48.821%
Evolutionary Genomics, Inc. 7.94 Million USD -347.229%
Finch Therapeutics Group, Inc. 48.11 Million USD 26.14%
Galera Therapeutics, Inc. 157.32 Million USD 77.413%
Innovation1 Biotech Inc. 3.5 Million USD -913.561%
Kiromic BioPharma, Inc. 21.28 Million USD -66.911%
Molecular Templates, Inc. 31.17 Million USD -14.0%
Navidea Biopharmaceuticals, Inc. 12.51 Million USD -183.941%
NexImmune, Inc. 5.08 Million USD -598.926%
Panbela Therapeutics, Inc. 16.51 Million USD -115.207%
Point of Care Nano-Technology, Inc. 266.41 Thousand USD -13238.263%
PaxMedica, Inc. Common Stock 2.29 Million USD -1448.142%
Scopus BioPharma Inc. 7.45 Million USD -376.696%
Sorrento Therapeutics, Inc. 494.5 Million USD 92.814%
Statera Biopharma, Inc. 22.67 Million USD -56.704%
TRACON Pharmaceuticals, Inc. 10.91 Million USD -225.591%
Trevena, Inc. 48.26 Million USD 26.371%
Vaxxinity, Inc. 30.94 Million USD -14.836%
Vaccinex, Inc. 5.94 Million USD -498.031%
Vicapsys Life Sciences, Inc. 1.96 Million USD -1705.331%
Viracta Therapeutics, Inc. 38.37 Million USD 7.396%
ZIVO Bioscience, Inc. 2.76 Million USD -1186.774%